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Universitario Ramón y Cajal, IRYCIS, Madrid, SpainAbstractPrevalence of transmitted drug resistance (pTDR) to antiretroviral
drugs in Spain (2007–2012) was estimated using the CoRIS cohort,
adjusting its territorial distribution and transmission route to the
reference population from the Spanish Information System on
New human immunodeﬁciency virus diagnoses. A total of 2702
patients from ten autonomous communities and with naive
FASTA sequence within 6 months of human immunodeﬁciency
virus diagnosis were selected. Weighted pTDR, estimated using
the inverse probability of selection in the sample by autonomous
communities and transmission group, was 8.12% (95% CI
6.44–9.80), not signiﬁcantly different from unweighted pTDR.
We illustrate how proportional weighting can maximize
representativeness of cohort-based data, and its value to monitor
pTDR at country level.
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E-mail: smonge@isciii.esEpidemiological surveillance of human immunodeﬁciency virus
(HIV) infection provides an invaluable input for public health
policy development and programme planning and evaluation. In
Spain, there is a national surveillance system for new HIV and
AIDS diagnoses but no system has been established for sur-
veillance of transmitted drug resistance (TDR) in newly diag-
nosed HIV-infected patients. TDR due to transmitted mutations
in reverse transcriptase and protease regions has been associ-
ated with a higher risk of virological failure to ﬁrst-line antire-
troviral therapy [1], so this information is of great value for
informing national recommendations.
The cohort of the Spanish AIDS Research Network (CoRIS)
is an open, multicentre, prospective cohort of HIV-positive,
antiretroviral-naive subjects over 13 years of age. It started
recruiting in 2004; 31 HIV units from 13 of the 17 autonomous
communities of Spain participate. Descriptions of the cohort
have been previously published [2,3]. However, territorial dis-
tribution of cases varies according to number and size of hos-
pitals contributing to CoRIS and is misbalanced compared with
the Spanish Information System on New HIV-diagnoses (SINI-
VIH) [4]. CoRIS collects FASTA sequences encoding the HIV
reverse transcriptase and protease, if available, from routine
resistance testing. Previous studies on TDR have been pub-
lished for data between 2004 and 2011 [5–7]. As of December
2012, 29 sites from ten autonomous communities were
contributing FASTA sequences.
This study used FASTA sequences available in the CoRIS
cohort to estimate the national prevalence of TDR and esti-
mated phenotypic resistance to antiretroviral drugs in patients
diagnosed in the period 2007–2012 in Spain, adjusting its ter-
ritorial distribution and transmission route to the corre-
sponding surveillance data.
We selected the ﬁrst sequence for each patient available
while naive to antiretroviral therapy and within the ﬁrst 6
months after the ﬁrst HIV diagnosis [8,9]. TDR-associatedClin Microbiol Infect 2015; 21: 105.e1–105.e5
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drug resistance mutation list updated in 2009 by Bennett et al.
[10]. Phenotypic resistance to antiretroviral drugs making part
of recommended initial regimens was predicted using the
Stanford HIVdb v6.3.2 algorithm [11,12].
Considering CoRIS as a sample of the cases notiﬁed in the
SINIVIH, weights were calculated as the inverse probability of
being selected, multiplied by total patients for a constant sample
size. The selection probability was derived by dividing the
number in each autonomous community infected though a
particular route in CoRIS by the total number of persons in
those categories in the SINIVIH. Weighted prevalences and
their 95% CI were calculated.
Of 5773 patients in CoRIS, 2702 fulﬁlled inclusion criteria.
Included patients had a higher proportion of males (89.4%
versus 85.6%), men who have sex with men (MSM; 72.4%
versus 64.6%), Spanish (71.5% versus 68.0%) and were younger
(median of 33.7 versus 34.4 years); all differences signiﬁcant at
p < 0.01. Median CD4 count was also higher (419; interquartile
range 256–612 versus 400; 230–600; p < 0.01). ComparedTABLE 1. Characteristics of the cohort of the Spanish AIDS
Research Network (CoRIS) sample: non-weighted and
weighted proportions; comparison with characteristics of the
Spanish Information System on New HIV-diagnoses
(SINIVIH; 2007–2012 aggregated)
CoRIS (n [ 2702)
SINIVIH (n [ 21210)Non-weighted Weighteda
n (%) (%) n (%)
Transmission category
IDU 85 (3.1) (6.6) 1397 (6.6)
MSM 1955 (72.4) (50.2) 10 640 (50.2)
HET 595 (22.0) (32.5) 6890 (32.5)
Other 23 (0.9) (10.8) 2283 (10.8)
Unknown 44 (1.6)
Sex
Men 2421 (89.6) (82.7) 17 204 (81.1)
Women 281 (10.4) (17.3) 4006 (18.9)
Age (years)
15–19 36 (1.3) (1.3) 316 (1.5)
20–24 341 (12.6) (10.6) 2004 (9.4)
25–29 542 (20.1) (15.9) 3681 (17.4)
30–39 1019 (37.7) (37.6) 7816 (36.8)
40–49 511 (18.9) (21.3) 4858 (22.9)
50 253 (9.4) (13.3) 2535 (12.0)
Region of origin
Spain 1933 (71.5) (73.0) 12 974 (61.2)
Western Europe 92 (3.4) (3.2) 910 (4.3)
Eastern Europe 55 (2.0) (2.6) 697 (3.3)
Sub-Saharan Africa 81 (3.0) (3.7) 1829 (8.6)
Northern Africa 27 (1.0) (1.1) 268 (1.3)
Latin America 498 (18.4) (15.8) 4337 (20.4)
Other/Unknown 16 (0.6) (0.6) 195 (0.9)
CD4 count (cells/mm3)
<200 475 (17.6) (22.8) 6213 (29.3)
200–349 545 (20.2) (21.3) 3950 (18.6)
>349 1643 (60.8) (52.6) 11 047 (52.1)
Unknown 39 (1.4) (3.3) (12.4)
Abbreviations: IDU, injecting drug user; MSM, men who have sex with men; HTX,
heterosexual exposure.
aWeighted sample: inverse weights for the probability of being selected in the
sample according to Autonomous Community and Transmission category.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectwith the SINIVIH and before weighting, we similarly found an
over-representation of younger males, MSM and Spanish. After
weighting, the proﬁle became more similar to SINIVIH,
although an infra-representation of foreigners persisted
(Table 1). Weights are shown in Table 2.
Results were not signiﬁcantly different in weighted and un-
weighted models (all p > 0.10), probably indicating that the
CoRIS cohort is highly representative of the current Spanish
epidemic. Weighted prevalence of TDR and weighted predicted
phenotypic resistance were, respectively: 8.12% (95% CI
6.44–9.80) and 10.67% (9.51–11.84) globally; 3.62%
(2.52–4.74) and 2.29% (1.53–3.06) for nucleoside reverse
transcriptase inhibitors; 3.37% (2.28–4.46) and 8.53%
(7.04–10.01) for non-nucleoside reverse transcriptase in-
hibitors; and 2.17% (1.23–3.11) and 0.74% (0.31–1.16) for
protease inhibitors. The incorporation of E138A as a mutation
for rilpivirine in the Stanford algorithm was responsible for the
higher predicted resistance to non-nucleoside reverse tran-
scriptase inhibitors. E138A is a frequently detected mutation in
antiretroviral-naive patients as a singleton, but there is no evi-
dence so far on its real impact; the exact role of this and other
singletons in this codon merits further study.
Surveillance of TDR in newly diagnosed patients is of
outmost importance for monitoring the emergence and spread
of resistant variants in a population, and has direct implications
in HIV management policies and recommendations [13,14].
Our analysis illustrates how proportional weighting can be used
to maximize representativeness of cohort-based data. In a
similar way, Hofstra et al. and Vercauteren et al. estimated theTABLE 2. Sample size by autonomous community in the
Spanish Information System on New HIV-diagnoses
(SINIVIH) and in the non-weighted cohort of the Spanish
AIDS Research Network (CoRIS) sample and calculated
weights by autonomous communities and transmission group
Autonomous
community
Sample size by AC Calculated weights
SINIVIH CoRIS Sample
IDU MSM HTX OTH/UNKn (%) n (%)
Andalusia 3546a (16.72) 717 (26.54) 1.35 0.43 0.95 4.42
Balearic Islands 1034 (4.88) 62 (2.29) 2.04 1.71 2.45 8.41
Basque Country 1114 (5.25) 119 (4.40) 2.22 0.79 1.52 3.54
Canary Islands 1562 (7.39) 69 (2.55) 10.70 2.21 5.03 6.88
Catalonia 4423 (20.85) 200 (7.40) 5.72 2.17 3.11 9.68
Galicia 1216 (5.73) 88 (3.26) 4.18 1.40 1.73 4.40
La Rioja 129 (0.61) 44 (1.63) 1.02 0.14 0.47 0.45
Navarre 195 (0.92) 42 (1.55) 1.53 0.59 0.57 0.51
Madrid 6042 (28.49) 1233 (45.63) 1.37 0.47 1.15 2.08
Valencian
Community
1943a (9.16) 128 (4.74) 1.00 1.14 1.85 10.79
Abbreviations: AC, autonomous community; IDU, injecting drug user; MSM, men
who have sex with men; HTX, heterosexual exposure; OTH/UNK, other or
unknown route of transmission.
aEstimated parameter, ofﬁcial estimates from the National Surveillance System,
SINIVIH.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 105.e1–105.e5
CMI Monge et al. Cohort-based Estimation of TDR Prevalence 105.e3prevalence of TDR in the SPREAD programme using either
representative sampling [15] or weighted means [16] for
transmission route and country, considering their respective
share in the European epidemic.
The clinical indication of resistance testing could inﬂuence
our results, but the restriction to patients diagnosed after 2007,
when the recommendation to screen for resistance in all pa-
tients was issued, minimizes the potential bias [17]. The higher
compliance with this recommendation in younger males, MSM
and those of Spanish origin is likely to reﬂect better linkage to
the healthcare system and higher agency of these patients, rather
than selection based on suspected resistance; but we cannot rule
out that certain selection bias persists at a small scale.
In this study, we could only weight by autonomous com-
munity and transmission route. However, characteristics of the
weighted sample were fairly similar to SINIVIH, with only an
infra-representation of foreigners persisting. It is unclear how
this limitation may have inﬂuenced our results, although in our
previous reports [6] we found no association of region of origin
with TDR. It was not possible to investigate weighted temporal
trends because of the limited sample size. However, our results
indicate that CoRIS is representative of new HIV diagnoses, so
the stable trend for total TDR and decreasing trend for pre-
dicted phenotypic resistance previously communicated [7] can
probably be extrapolated to country level.
Although not all autonomous communities in Spain are
represented in this study, we succeeded in including the areas
with the higher concentration of HIV cases, representing 78%
of the Spanish population, but 85% of new HIV diagnoses [18].
In conclusion, we think that cohort-based data can provide
valid estimates of the national prevalence of HIV TDR in pa-
tients with newly diagnosed HIV infection; and although in our
study we did not observe a signiﬁcant difference when using
proportional weighting to maximize national representative-
ness, we consider it is of paramount importance to take
representativeness into account, and we describe a convenient
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